Integrating Omics in R&D: A new era of biomedical research

Immune Profile Score (IPS) Overview

Explore the limitations of current biomarkers and learn how Immune Profile Score (IPS) helps address these challenges by combining DNA and RNA data to provide prognostic insights into immune checkpoint inhibitor (ICI) treatment outcomes in metastatic solid tumors.

Read more

ADCs in focus: The next generation of precision medicine in oncology

Watch this engaging discussion as thought leaders explore the evolving landscape of antibody-drug conjugates (ADCs) in cancer therapeutics, including resistance mutations in first-gen ADCs, combination strategies with immune checkpoint inhibitors (ICIs), and next-gen targets and technologies. Tempus is dedicated to enhancing ADC development by offering comprehensive genomic profiling, multimodal de-identified real-world data (RWD), and AI-enabled solutions, informing target discovery and clinical trial optimization for more personalized therapies.

Watch replay

Advancing transcriptional cancer therapies with Tempus’ comprehensive life science solutions

Kronos Bio, a trailblazer in the biopharmaceutical industry, is dedicated to the discovery and development of novel therapies that target transcriptional regulation in cancer. Kronos turned to Tempus’ comprehensive suite of solutions to propel its principal asset from discovery to clinical trials.

Read more